Home / Press / CMS advises investor group on financing Allecra T...

CMS advises investor group on financing Allecra Therapeutics


Munich – Allecra Therapeutics, an antibiotics developer from the European BioValley life sciences cluster in the upper Rhine Valley, has completed a Series B round of financing totalling EUR 22 million. Investors include the Dutch life sciences venture capital financier Forbion Capital Partners, Paris-based Edmond de Rothschild Investment Partners and EMBL Ventures from Heidelberg. This group of investors previously financed the formation of Allecra Therapeutics by providing EUR 15 million in 2013.

A team from CMS Germany headed by Munich-based partner Stefan-Ulrich Müller advised the investor group on legal aspects of the financing. The investors are long-standing clients of CMS Germany.

Allecra Therapeutics develops antibiotics against multidrug-resistant Gram-negative bacteria. The new capital is earmarked primarily for a phase II study of the most advanced candidate drug compound, AAI202, scheduled to commence in the first half of 2017. AAI202 is a combination drug mainly intended to combat infections with ESBL bacteria that are occurring with increasing frequency in hospitals.

CMS Hasche Sigle

Stefan-Ulrich Müller, Lead Partner
Dr Tilman Weichert, Counsel
Dr Tobias Kallmaier, Senior Associate
Klara Brütting, Associate, all Venture Capital
Roland Wutzke, Partner, Tax

Press Contact
[email protected]

Press Release Forbion EMBL Ventures, 20/06/2016
PDF 119 kB

Related people

Stefan-Ulrich Müller
Stefan-Ulrich Müller, M. Jur. (Oxford)
Tilman Weichert
Dr. Tilman Weichert
Dr. Tobias Kallmaier